VYT — Vytrus Biotech SA Balance Sheet
0.000.00%
- €64.60m
- €62.73m
- €5.04m
- 92
- 10
- 91
- 76
Annual balance sheet for Vytrus Biotech SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1.09 | 1.28 | 0.725 | 1.11 | 2.53 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.214 | 0.265 | 0.531 | 0.782 | 0.727 |
| Total Inventory | |||||
| Total Current Assets | 1.54 | 1.82 | 1.68 | 2.45 | 3.79 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.575 | 0.678 | 1.03 | 0.93 | 0.856 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 6.21 | 7.18 | 8 | 9.31 | 11.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.643 | 0.806 | 1.27 | 0.996 | 1.25 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.6 | 2.93 | 3.25 | 4.02 | 3.84 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 3.61 | 4.25 | 4.75 | 5.29 | 7.29 |
| Total Liabilities & Shareholders' Equity | 6.21 | 7.18 | 8 | 9.31 | 11.1 |
| Total Common Shares Outstanding |